America Great Health Reports Clinical Observation Study Update on Ion-Modified Peptides

What Happened
America Great Health (AAGH) filed an 8-K on August 24, 2026 updating a clinical observation study of ion-modified peptide products AX-3 (Ion Peptide No. 1) and PPY-3 (Ion Peptide No. 4). The study was conducted at Zhejiang Kangjing Hospital from December 2024 through May 2026 and included 10 subjects (eight with solid tumors, one with malignant lymphoma, and one with bronchiectasis and hemoptysis). The peptides were used as adjunctive (add-on) treatment alongside other therapies; the hospital report notes varied clinical observations over baseline, ~1 month, ~3 months and ~6 months and states no significant treatment-related toxicity was identified other than discomfort swallowing large capsules. Two subjects with advanced disease died about 25 and 22 days after starting observation; both deaths were attributed to advanced disease and multiple-organ failure.

Key Details

• Study period: December 2024 – May 2026; number of subjects: 10 (8 solid tumors: 5 lung, 2 colorectal, 1 liver; 1 lymphoma; 1 bronchiectasis).
• Treatment context: AX-3 and PPY-3 administered as adjunctive therapy; many cancer subjects also received chemotherapy, radiation, surgery and/or targeted therapy.
• Safety/efficacy notes: Hospital report observed symptom improvements in some subjects and changes in blood and immune markers, but results varied; no significant treatment-related toxicity reported aside from swallowing discomfort.
• Limitations: Small, non-randomized, unblinded observational study with heterogeneous patients and concurrent therapies; company furnished the hospital report and patient observation tables as Exhibits 99.1 and 99.2.

Why It Matters
This is an early, preliminary data update—not a controlled clinical trial—so the observations cannot establish safety or effectiveness of AX-3, PPY-3, or any AAGH product. For investors, the filing signals that AAGH has completed a small observational clinical program that may guide future research, but it does not change the company’s regulatory or commercial prospects by itself. Any material progress will depend on larger, controlled studies and regulatory review; the company cautions there is no assurance these observations will be replicated or lead to approved products.